Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Cressey

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
Plos One|April 24, 2018
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trialAnna Turkova, Cecilia L Moore, Karina Butler, et al.
The Lancet. HIV|February 20, 2025
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialEllen White, Cissy Kityo, Moira J Spyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2026
Hypertension in a randomized trial of dolutegravir- versus efavirenz-based antiretroviral therapy in pregnant and postpartum women with HIVRisa Hoffman, Sean Brummel, Mauricio Pinilla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 18, 2010
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapineMarc Lallemant, Nicole Ngo-Giang-Huong, Gonzague Jourdain, et al.
Antimicrobial Agents and Chemotherapy|December 29, 2025
Pharmacokinetics and safety of fosfomycin and flomoxef administered as part of neonatal sepsis treatment (NeoSep1 Part 1)Adrie Bekker, Navarat Panjasawatwong, Louise F Hill, et al.
BMC Infectious Diseases|January 15, 2021
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosingCecilia L Moore, Anna Turkova, Hilda Mujuru, et al.
The Lancet. Gastroenterology & Hepatology|April 18, 2021
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trialIsabelle Andrieux-Meyer, Soek-Siam Tan, Sombat Thanprasertsuk, et al.
Open Forum Infectious Diseases|June 3, 2026
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized TrialHilda Angela Mujuru, Ellen White, Adeodata R Kekitiinwa, et al.
The Lancet. Child & Adolescent Health|January 24, 2026
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Avy Violari, et al.
The Pediatric Infectious Disease Journal|May 29, 2025
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 ResultsHelena Rabie, Dwight E Yin, Shawn Ward, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Plos One|April 24, 2018
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trialAnna Turkova, Cecilia L Moore, Karina Butler, et al.
The Lancet. HIV|February 20, 2025
Virological outcomes and genotypic resistance on dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trialEllen White, Cissy Kityo, Moira J Spyer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 13, 2026
Hypertension in a randomized trial of dolutegravir- versus efavirenz-based antiretroviral therapy in pregnant and postpartum women with HIVRisa Hoffman, Sean Brummel, Mauricio Pinilla, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 18, 2010
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapineMarc Lallemant, Nicole Ngo-Giang-Huong, Gonzague Jourdain, et al.
Antimicrobial Agents and Chemotherapy|December 29, 2025
Pharmacokinetics and safety of fosfomycin and flomoxef administered as part of neonatal sepsis treatment (NeoSep1 Part 1)Adrie Bekker, Navarat Panjasawatwong, Louise F Hill, et al.
BMC Infectious Diseases|January 15, 2021
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosingCecilia L Moore, Anna Turkova, Hilda Mujuru, et al.
The Lancet. Gastroenterology & Hepatology|April 18, 2021
Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trialIsabelle Andrieux-Meyer, Soek-Siam Tan, Sombat Thanprasertsuk, et al.
Open Forum Infectious Diseases|June 3, 2026
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized TrialHilda Angela Mujuru, Ellen White, Adeodata R Kekitiinwa, et al.
The Lancet. Child & Adolescent Health|January 24, 2026
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trialAnna Turkova, Ellen White, Avy Violari, et al.
The Pediatric Infectious Disease Journal|May 29, 2025
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 ResultsHelena Rabie, Dwight E Yin, Shawn Ward, et al.
Pageof 16